BET inhibitors have shown promise in treating various cancer types, including hematological malignancies such as acute myeloid leukemia (AML) and multiple myeloma, as well as solid tumors like breast cancer, lung cancer, and prostate cancer. The efficacy of BET inhibitors in these cancers is attributed to the dependency of these malignancies on specific oncogenic transcription programs.
